Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium carbonate plus riluzole in amyotrophic lateral sclerosis
2008-006722-34Phase 3Terminated
- Sponsor
- Istituto Superiore di Sanità
- Start
- Dec 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in amyotrophic lateral sclerosis (ALS) comparing Lithium carbonate + riluzole with Placebo + riluzole (2 arms). Primary endpoint: Overall survival at 18 months. Started Dec 2008; status: terminated.
02
Drugs
lithium carbonateriluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2008-006722-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006722-34.